Latest news with #BE
Time of India
a day ago
- Business
- Time of India
Beyond eye candy: A Cannes Lions Creative Data Special: BE Extraordinary
At the Cannes Lions International Festival of Creativity, a wide spectrum of creative work is recognised, extending beyond Grand Prix winners to include notable campaigns that earn silvers and bronzes. In " BE Extraordinary ," a series collaborating with Harsh Kapadia, CCO, Grey India , we highlight work that warrants discussion for its execution and results. This segment focuses on campaigns that effectively utilised data to drive their creative strategy and generate significant outcomes. Acko - Acko Tailor Test - Leo India Acko, a digital insurance company in India, utilised a unique insight into local health behaviors for its "Acko Tailor Test" campaign, developed in collaboration with Leo India. The core premise was based on the medical insight that the difference between a person's waistline and hipline can serve as an indicator of potential heart conditions. Recognising a prevalent cultural behavior in India, particularly among lower-income segments, where regular visits to tailors for clothing adjustments are common, but doctor visits might be avoided due to cost or access, Acko integrated a preventative health screening into this existing routine. The campaign involved training tailors across the country to use a specific chart to accurately measure clients' waist and hip ratios. Based on these measurements, tailors were empowered to advise individuals if their ratios suggested a potential heart condition, recommending a consultation with a doctor for further assessment. This grassroots approach effectively leveraged an accessible and trusted community point of contact to deliver crucial health information, demonstrating a data-driven strategy for promoting preventative health and early detection. Efficient Way To Pay - Consul Appliances, DM9 São Paulo In Brazil, a common challenge faced by many households is their reliance on outdated and inefficient electronic appliances. While often a result of financial constraints, these older models paradoxically lead to higher electricity bills, hindering their ability to save for newer, more efficient replacements. Consul Appliances, in collaboration with DM9 São Paulo, developed the "Efficient Way To Pay" program to address this economic cycle. The campaign leveraged data on energy consumption to directly demonstrate that replacing older electronics with new, energy-efficient Consul appliances would result in tangible savings on monthly electricity bills. Consul then designed an innovative payment plan: these verified electricity bill savings could be directly allocated to pay off the cost of the new appliances. This initiative effectively established a novel ecosystem for appliance purchasing. By creating a clear, data-driven economic model, Consul Appliances empowered consumers to upgrade their household electronics, turning their ongoing energy expenses into a means of financing more sustainable and cost-effective solutions. So Many Dicks - ELF Beauty, New York ELF Beauty, an American beauty brand, utilised compelling data to drive its "So Many Dicks" campaign, focusing on corporate diversity. The campaign stemmed from research that revealed a significant majority of corporate board members were white men. Strikingly, the data further highlighted that more men named "Dick" held board positions than entire groups of underrepresented people combined. As a company that itself boasts a board composed of 78 per cent women and 44 per cent diverse individuals, ELF Beauty leveraged this data to create a viral campaign that directly called attention to the lack of diversity in corporate boardrooms. The campaign's aim was to spark conversations and actively promote change. ELF directly linked diversity to profitability through a "not so white paper" they released, and collaborated with organisations like the National Association of Corporate Directors (NACD) to facilitate the successful placement of diverse candidates on corporate boards. This data-driven approach allowed ELF Beauty to advocate for tangible change in corporate governance, grounded in both ethical considerations and demonstrated business success. Ikea Hidden Tags - Ikea (Portugal), Uzina Ikea in Portugal, in collaboration with Uzina, embarked on a campaign titled "Ikea Hidden Tags" to address a common perception among consumers that its furniture is not built for durability. The brand ingeniously utilised an existing, yet often overlooked, piece of internal product data: a small, hidden tag on every Ikea furniture item that indicates its precise manufacturing date. To directly counter the misconception about product longevity, Ikea launched a country-wide "Tag Hunt." This initiative invited customers to actively participate by locating these hidden tags on their Ikea furniture to determine its age. A significant prize was offered for the oldest piece of Ikea furniture found in Portugal. This campaign effectively transformed a simple internal product detail into an engaging, interactive contest. By encouraging customers to physically examine their furniture and discover its actual age, Ikea leveraged existing customer ownership and direct interaction with the furniture's embedded data to demonstrate the unexpected durability and longevity of its products firsthand. (At BE Extraordinary, a series about the winners at Cannes Lions in collaboration with Harsh Kapadia, CCO, Grey India, we peer outside the Grand Prix, and look at clutter breaking work that picked the silvers and the bronzes, but don't often get discussed.)
Yahoo
11-06-2025
- Business
- Yahoo
BIMZELX® (bimekizumab-bkzx) Three-Year Data at EULAR 2025 Showed Lasting Efficacy and Control of Inflammation in Psoriatic Arthritis and Axial Spondyloarthritis
Sustained symptom relief in patients with psoriatic arthritis: Achievement of the stringent ACR50 endpoint was sustained at three years by 53.2% and 55.2% of patients with psoriatic arthritis (PsA) naïve to biologics or who had an inadequate response to, or were intolerant of, tumor necrosis factor inhibitors, respectively†* Lasting improvements in physical function across the full spectrum of patients with axial spondyloarthritis: ASAS40, a composite endpoint, was sustained at three years by 60.4% and 60.1% of patients with non-radiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS), respectively¥* Long-term inflammation control through three years: New data demonstrated consistent sustainability of efficacy across stringent clinical endpoints in PsA, nr-axSpA, and AS, showing potential to improve long-term outcomes and prevent structural damage Dual inhibition: BIMZELX® is the first and only approved medicine designed to selectively inhibit interleukin 17A (IL-17A) in addition to interleukin 17F (IL-17F) ATLANTA, June 11, 2025 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced new three-year data from Phase 3 trials, and their open-label extensions, investigating BIMZELX® (bimekizumab-bkzx) in adults with active psoriatic arthritis (PsA) and active axial spondyloarthritis (axSpA), which includes both non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation and ankylosing spondylitits (AS). BIMZELX, a dual inhibitor of IL-17A and IL-17F,1 demonstrated sustained control of inflammation and deep efficacy in patients living with PsA and axSpA,2-5 chronic inflammatory diseases with considerable impact on physical and emotional wellbeing.6-7 Sustained symptom relief in patients with active psoriatic arthritis "A primary treatment goal in psoriatic arthritis is sustained control of inflammation to help prevent long-term, irreversible structural damage and to improve quality of life," said Professor Laure Gossec,‡ from the Sorbonne University Hospital, Paris, France. "These bimekizumab data are notable for their consistency across treatment-naïve and experienced patients, with elimination of swollen joints in nearly sixty percent of patients and approximately half reaching minimal disease activity (MDA) at three years – both strong clinical responses that suggest real control of inflammation in PsA." In patients with active PsA, regardless of prior treatment experience, results from BE OPTIMAL, BE COMPLETE, and their open-label extension, BE VITAL, showed that BIMZELX delivered sustained efficacy across multiple stringent clinical endpoints for up to three years.2-3 At three years, 59.5% and 59.1% of bDMARD-naïve and TNFi-IR patients, respectively, achieved elimination of swollen joints (SJC=0).†*2-3 Complete skin clearance, measured by Psoriasis Area and Severity Index [PASI]100, was sustained to three years by 61.9% and 67.5% of bDMARD-naïve and TNFi-IR patients, respectively.†*2-3 MDA, a comprehensive and clinically meaningful endpoint, was sustained to three years by 52.9% and 48.8% of bDMARD-naïve and TNFi-IR patients, respectively.†*2-3 Improvements in physical function across the full spectrum of patients with axial spondyloarthritis "Long-term data, showing that patients living with axSpA can maintain high levels of clinical response, are invaluable for informed treatment decisions. It's particularly compelling to see sustained responses with bimekizumab treatment at three years with stringent outcome measures like ASAS40 and low disease activity," said Professor Xenofon Baraliakos,‡ from the Rheumazentrum Ruhrgebiet Herne, Ruhr University Bochum, Bochum, Germany. "These endpoints are key indicators of durable inflammation control in axSpA, and achieving this level of sustained disease management is likely to have a profound impact on patients' daily lives." Across patients with nr-axSpA and AS, data from two Phase 3 studies, BE MOBILE 1 and 2, and their combined open-label extension, BE MOVING, BIMZELX treatment demonstrated sustained clinical responses up to three years.4 Achievement of ASAS40 was sustained to three years by 60.4% and 60.1% of nr-axSpA and AS patients, respectively*, while 61.8% and 59.9% of nr-axSpA and AS patients, respectively, maintained Axial Spondyloarthritis Disease Activity Score (ASDAS) low disease activity (LDA <2.1) through three years.¥±4 Long-term inflammation control in patients with PsA and axSpA "Psoriatic arthritis and axial spondyloarthritis are serious, chronic inflammatory diseases that can have a great impact in the daily lives of patients and their families. The data presented at EULAR reinforce the role of bimekizumab to deliver deep, consistent, and sustained outcomes across a spectrum of PsA and axSpA," said Donatello Crocetta, Chief Medical Officer, UCB. "These data, alongside our other EULAR data presentations of dapirolizumab pegol§ in systemic lupus erythematosus and romosozumab in osteoporosis, reflect UCB's commitment to offering differentiated, science-driven solutions that meet the diverse and evolving needs of people living with rheumatic diseases." Across the three-year clinical trial data for PsA and axSpA, BIMZELX was generally well-tolerated and no new safety signals were observed.2-4 The most common treatment-emergent adverse events (TEAEs) over three years for both PsA and axSpA in these studies were SARS-CoV-2 (COVID-19) infection, nasopharyngitis, and upper respiratory tract infection.2-4 UCB will present 14 abstracts on PsA and axSpA at EULAR 2025 in Barcelona, Spain, June 11-14, and will complement other presentations from UCB in systemic lupus erythematosus and osteoporosis. These data, together with a dedication to advancing clinical research – including the ongoing head-to-head Phase 3b BE BOLD trial in psoriatic arthritis – underscore UCB's ambition to be a leader in rheumatology, commitment to advancing innovation, and focus on providing meaningful solutions across the spectrum of rheumatic diseases. †PsA data reported from BE OPTIMAL, BE COMPLETE, and their open-label extension (OLE), BE VITAL, for patients in the BKZ Total group (PBO/BKZ patients and BKZ-randomized patients). BE OPTIMAL (bDMARD-naïve) Week 52 and BE COMPLETE (TNFi-IR) Week 16 completers were eligible for the BE VITAL open-label extension.2-3 *mNRI: Modified non-responder imputation (binary). All visits following discontinuation due to adverse events or lack of efficacy were treated as non-response, other reasons for missing data were calculated using multiple imputation (MI).2-4 ¥axSpA trials BE MOBILE 1 (nr-axSpA) and BE MOBILE 2 (AS) each comprised a 16-week, double-blind, placebo-controlled period and a 36-week maintenance period. All patients received subcutaneous BKZ 160 mg every 4 weeks (Q4W) from Week 16.4 At Week 52, eligible patients could enter the OLE, BE MOVING.4 Of 586 randomized patients (nr-axSpA: 254; AS: 332), 494 (84.3%) patients entered the OLE at Week 52.4 Data presented include patients originally randomized to placebo; all patients were treated with BKZ 160 mg Q4W from Week 16.4 ±Multiple imputation (MI). ‡co-author. §Dapirolizumab pegol is an investigational drug and is not approved for use in systemic lupus erythematosus by any regulatory authority worldwide. Notes to Editors: ACR50: A 50% or greater improvement from baseline in American College of Rheumatology response criteria, including at least a 50% improvement in tender and swollen joint counts as well as 50% improvement in three additional criteria (physician global, patient global, patient pain, function, and CRP/erythrocyte sedimentation rate).8 This represents a stringent efficacy outcome in PsA9-10 ASAS40: Assessment of SpondyloArthritis International Society 40%, a composite endpoint covering a core set of domains that should be assessed in axSpA patients.11 This core set of domains includes physical function, morning stiffness, patient global assessment, and pain.11 In order to meet an ASAS40 response, three of the four domains should improve by at least 40% and a minimum of two units on a scale of 0 to 10. In the remaining domain, there should be no worsening of 20% and a minimum of 1 unit, on a 0 to 10 scale.11 TNFi-inadequate response (TNFi-IR): Patients with PsA who experience prior inadequate response or intolerance to tumor necrosis factor inhibitors3 bDMARD-naïve: Patients who had not previously taken a biologic disease-modifying antirheumatic drug (bDMARD)2 About Psoriatic Arthritis Psoriatic arthritis is a serious, highly heterogeneous, chronic, systemic inflammatory condition affecting both the joints and skin with a prevalence of 0.02 percent to 0.25 percent of the population.12 Psoriatic arthritis affects approximately 30 percent of people living with psoriasis.13 It manifests as joint pain and stiffness, skin plaques, swollen toes and fingers (dactylitis), and inflammation of the sites where tendons or ligaments insert into the bone (enthesitis).14 The burden on those living with PsA extends beyond physical discomfort to reduced quality of life, with comorbidities including hypertension, cardiovascular disease, and depression.6 In PsA, uncontrolled active disease can lead to long-term, irreversible structural damage.15 About BE OPTIMAL and BE COMPLETE BE OPTIMAL and BE COMPLETE were two Phase 3 studies evaluating the efficacy and safety of BIMZELX in the treatment of psoriatic arthritis.16 The primary endpoint in both studies was the proportion of patients reaching 50% or greater improvement in American College of Rheumatology criteria (ACR50) at Week 16.16 BE OPTIMAL (bDMARD-naïve) and BE COMPLETE (TNFi-IR) assessed subcutaneous BIMZELX 160 mg every four weeks (Q4W) in patients with PsA; both studies were placebo-controlled to Week 16, after which placebo patients switched to BIMZELX.16 BE OPTIMAL Week 52 and BE COMPLETE Week 16 completers were eligible for BE VITAL open-label extension.16 About Axial Spondyloarthritis Axial spondyloarthritis (axSpA), which includes both non-radiographic axSpA (nr-axSpA) and ankylosing spondylitis (AS), is a chronic, immune-mediated, inflammatory disease.7 nr-axSpA is defined clinically by the absence of definitive x-ray evidence of structural damage to the sacroiliac joints.7 axSpA is a painful condition that primarily affects the spine and the joints linking the pelvis and lower spine (sacroiliac joints).7 The leading symptom of axSpA in a majority of patients is inflammatory back pain that improves with exercise, but not with rest.7 Other common clinical features frequently include anterior uveitis, enthesitis, peripheral arthritis, psoriasis, inflammatory bowel disease, and dactylitis.7 The overall prevalence of axSpA is 0.3 percent to 1.3 percent of adults.17-18 Approximately half of all patients with axSpA are patients with nr-axSpA.7 axSpA onset usually occurs before the age of 45.7 Approximately 10 to 40 percent of patients with nr-axSpA progress to ankylosing spondylitis over 2 to 10 years.7 About BE MOBILE 1 and BE MOBILE 2BE MOBILE 1 and BE MOBILE 2 were two Phase 3 studies evaluating the efficacy and safety of BIMZELX in the treatment of nr-axSpA and AS, respectively.19 The primary endpoint in both studies was the Assessment of SpondyloArthritis international Society 40 percent (ASAS40) response at Week 16.19 BE MOBILE 1 and BE MOBILE 2 comprised a 16-week double-blind treatment period followed by a 36-week maintenance period.19 In BE MOBILE 1 and BE MOBILE 2, patients were randomized to BIMZELX (160 mg Q4W; n=128 for BE MOBILE 1 and n=221 for BE MOBILE 2) or to placebo (n=126 for BE MOBILE 1 and n=111 for BE MOBILE 2).19 Patients initially randomized to placebo were switched to BIMZELX (160 mg Q4W) at Week 16.19 BE MOBILE 1 and BE MOBILE 2 Week 52 completers were eligible for BE MOVING open-label extension.20 About BIMZELX® (bimekizumab-bkzx) BIMZELX is a humanized monoclonal IgG1 antibody that is designed to selectively inhibit both interleukin 17A (IL-17A) and interleukin 17F (IL-17F), two key cytokines driving inflammatory processes.1 IL-17A and IL-17F are key contributors of chronic inflammation and damage across multiple tissues, with IL-17F increasing over time.1,21-23 IL-17F is over-expressed in skin and highly elevated in the serum of patients with psoriasis (PSO), psoriatic arthritis (PsA), non-radiographic axial spondyloarthritis (nr-axSpA), ankylosing spondylitis (AS), and hidradenitis suppurativa (HS).1,21-24 The approved indications for BIMZELX in the U.S. are:1 Plaque psoriasis: BIMZELX is approved for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy Psoriatic arthritis: BIMZELX is indicated for the treatment of adult patients with active psoriatic arthritis Non-radiographic axial spondyloarthritis: BIMZELX is indicated for the treatment of adult patients with active non-radiographic axial spondyloarthritis with objective signs of inflammation Ankylosing spondylitis: BIMZELX is indicated for the treatment of adult patients with active ankylosing spondylitis Hidradenitis suppurativa: BIMZELX is indicated for the treatment of adult patients with moderate-to-severe hidradenitis suppurativa BIMZELX U.S. IMPORTANT SAFETY INFORMATION IMPORTANT SAFETY INFORMATION Suicidal Ideation and BehaviorBIMZELX (bimekizumab-bkzx) may increase the risk of suicidal ideation and behavior (SI/B). A causal association between treatment with BIMZELX and increased risk of SI/B has not been definitively established. Prescribers should weigh the potential risks and benefits before using BIMZELX in patients with a history of severe depression or SI/B. Advise monitoring for the emergence or worsening of depression, suicidal ideation, or other mood changes. If such changes occur, instruct to promptly seek medical attention, refer to a mental health professional as appropriate, and re-evaluate the risks and benefits of continuing treatment. InfectionsBIMZELX may increase the risk of infections, including serious infections. Do not initiate treatment with BIMZELX in patients with any clinically important active infection until the infection resolves or is adequately treated. In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing BIMZELX. Instruct patients to seek medical advice if signs or symptoms suggestive of clinically important infection occur. If a patient develops such an infection or is not responding to standard therapy, monitor the patient closely and do not administer BIMZELX until the infection resolves. TuberculosisEvaluate patients for tuberculosis (TB) infection prior to initiating treatment with BIMZELX. Avoid the use of BIMZELX in patients with active TB infection. Initiate treatment of latent TB prior to administering BIMZELX. Consider anti-TB therapy prior to initiation of BIMZELX in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Closely monitor patients for signs and symptoms of active TB during and after treatment. Liver Biochemical AbnormalitiesElevated serum transaminases were reported in clinical trials with BIMZELX. Test liver enzymes, alkaline phosphatase, and bilirubin at baseline, periodically during treatment with BIMZELX, and according to routine patient management. If treatment-related increases in liver enzymes occur and drug-induced liver injury is suspected, interrupt BIMZELX until a diagnosis of liver injury is excluded. Permanently discontinue use of BIMZELX in patients with causally associated combined elevations of transaminases and bilirubin. Avoid use of BIMZELX in patients with acute liver disease or cirrhosis. Inflammatory Bowel DiseaseCases of inflammatory bowel disease (IBD) have been reported in patients treated with IL-17 inhibitors, including BIMZELX. Avoid use of BIMZELX in patients with active IBD. During BIMZELX treatment, monitor patients for signs and symptoms of IBD and discontinue treatment if new onset or worsening of signs and symptoms occurs. ImmunizationsPrior to initiating therapy with BIMZELX, complete all age-appropriate vaccinations according to current immunization guidelines. Avoid the use of live vaccines in patients treated with BIMZELX. Most Common Adverse Reactions Most common (≥ 1%) adverse reactions in plaque psoriasis and hidradenitis suppurativa include upper respiratory tract infections, oral candidiasis, headache, injection site reactions, tinea infections, gastroenteritis, herpes simplex infections, acne, folliculitis, other candida infections, and fatigue. Most common (≥ 2%) adverse reactions in psoriatic arthritis include upper respiratory tract infections, oral candidiasis, headache, diarrhea, and urinary tract infections. Most common (≥ 2%) adverse reactions in non-radiographic axial spondyloarthritis include upper respiratory tract infections, oral candidiasis, headache, diarrhea, cough, fatigue, musculoskeletal pain, myalgia, tonsillitis, transaminase increase, and urinary tract infections. Most common (≥ 2%) adverse reactions in ankylosing spondylitis include upper respiratory tract infections, oral candidiasis, headache, diarrhea, injection site pain, rash, and vulvovaginal mycotic infection. Please see Important Safety Information below and full U.S. Prescribing Information at For further information, contact UCB: Investor Relations Antje Witte T +32.2.559.94.14 email: Brand Communications Nicole Herga T +1.773.960.5349 email: About UCB UCB, Brussels, Belgium ( is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 9,000 people in approximately 40 countries, the company generated revenue of €5.3 billion in 2023. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCBUSA. Forward looking statements This press release may contain forward-looking statements including, without limitation, statements containing the words "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will", "continue" and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management. All statements, other than statements of historical facts, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, arbitration, political, regulatory or clinical results or practices and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to differ materially from those that may be expressed or implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, product liability claims, challenges to patent protection for products or product candidates, competition from other products including biosimilars, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws, and hiring and retention of its employees. There is no guarantee that new product candidates will be discovered or identified in the pipeline, will progress to product approval or that new indications for existing products will be developed and approved. Movement from concept to commercial product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans. So far, the complexity of the human body cannot be reproduced in computer models, cell culture systems or animal models. The length of the timing to complete clinical trials and to get regulatory approval for product marketing has varied in the past and UCB expects similar unpredictability going forward. Products or potential products, which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences disputes between the partners or may prove to be not as safe, effective or commercially successful as UCB may have believed at the start of such partnership. UCB's efforts to acquire other products or companies and to integrate the operations of such acquired companies may not be as successful as UCB may have believed at the moment of acquisition. Also, UCB or others could discover safety, side effects or manufacturing problems with its products and/or devices after they are marketed. The discovery of significant problems with a product similar to one of UCB's products that implicate an entire class of products may have a material adverse effect on sales of the entire class of affected products. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment, including pricing pressure, political and public scrutiny, customer and prescriber patterns or practices, and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement activities and outcomes. Finally, a breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of UCB's data and systems. Given these uncertainties, you should not place undue reliance on any of such forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labelling in any market, or at any particular time, nor can there be any guarantee that such products will be or will continue to be commercially successful in the future. UCB is providing this information, including forward-looking statements, only as of the date of this press release. UCB expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report or reflect any change in its forward-looking statements with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless such statement is required pursuant to applicable laws and regulations. Additionally, information contained in this document shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any offer, solicitation or sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such jurisdiction. References BIMZELX® (bimekizumab-bkzx) U.S. Prescribing Information. Accessed June 2025. Gossec L, Coates L, McInnes I, et al. Bimekizumab, a dual inhibitor of IL-17A and IL 17F, demonstrated long-term safety and efficacy biologic DMARD naïve patients with active psoriatic arthritis: final 3-year results from the Phase 3 BE OPTIMAL study and its open label extension [abstract]. EULAR 2025. POS1294. McInnes I, Merola J, Coates L, et al. Dual inhibition of IL-17A and IL-17F with bimekizumab demonstrated long-term safety and efficacy in patients with active psoriatic arthritis and prior inadequate response to tumor necrosis factor inhibitors: final 3-year results from the Phase 3 BE COMPLETE study and its open-label extension [abstract]. EULAR 2025. POS0105. Baraliakos X, Deodhar A, van der Heijde D, et al. Bimekizumab demonstrated sustained efficacy and safety across the full spectrum of axial spondyloarthritis: 3-year results from two Phase 3 studies and their open-label extension [abstract]. EULAR 2025. POS0788. Navarro-Compán V, Kiltz U, Mease P, et al. Sustained improvements with bimekizumab in pain, morning stiffness, fatigue, physical function and health-related quality of life in patients with axial spondyloarthritis: 3-year results from two Phase 3 studies [abstract]. EULAR 2025. #POS0921. Lee S, Mendelsohn A, Sarnes E. The burden of psoriatic arthritis: A literature review from a global health systems perspective. P T. 2010;35(12):680–89. Deodhar A. Understanding Axial Spondyloarthritis: A Primer for Managed Care. Am J Manag Care. 2019;25:S319–30. Gladman DD, Mease PJ, Healy P, et al. Outcome measures in psoriatic arthritis. J Rheumatol. 2007;34(5):1159-66. Ritchlin C, Coates L, McInnes I, et al. Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study. Ann Rheum Dis. 2023:82(11);1404–14. Kerschbaumer A, Smolen JS, Ferreira RJO, et al. Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis. 2024;83(6):760-774. doi: 10.1136/ard-2024-225534. Landewé R, van Tubergen A. Clinical Tools to Assess and Monitor Spondyloarthritis. Curr Rheumatol Rep. 2015:17(7);47. Ogdie A, Weiss P. The Epidemiology of Psoriatic Arthritis. Rheum Dis Clin North Am. 2015:41(4);545–68. Mease PJ, Gladman DD, Papp KA, et al. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol. 2013;69(5):729-735. doi: 10.1016/ Mease P, Armstrong A. Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis. Drugs. 2014:74(4);423–41. Kwok T, Sutton M, Cook R, et al. Musculoskeletal Surgery in Psoriatic Arthritis: Prevalence and Risk Factors. J Rheumatol. 2023:50(4);497–503. Mease PJ, Merola JF, Tanaka Y, et al. Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies. Rheumatol Ther. 2024;11(5):1363-1382. doi: 10.1007/s40744-024-00708-8. Reveille J, Witter J, Weisman M. Prevalence of axial spondylarthritis in the United States: estimates from a cross-sectional survey. Arthritis Care Res (Hoboken). 2012:64(6);905–10. Hamilton L, Macgregor A, Toms A, et al. The prevalence of axial spondyloarthritis in the UK: a cross-sectional cohort study. BMC Musculoskelet Disord. 2015:10(16);392. Baraliakos X, Deodhar A, van der Heijde D, et al. Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies. Ann Rheum Dis. 2024:83(2);199–213. Baraliakos X, Deodhar A, van der Heijde D, et al. Long-term safety and efficacy of bimekizumab in axial spondyloarthritis: 2-year results from two phase 3 studies. Rheumatology (Oxford). 2025;64(6):3534-3546. doi: 10.1093/rheumatology/keaf009. Glatt S, Baeten D, Baker T et al. Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. Ann Rheum Dis. 2018;77:523–32. Gordon KB, Foley P, Krueger JG, et al. Bimekizumab efficacy and safety in moderate-to-severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomized withdrawal phase 3 trial. Lancet. 2021;397(10273):475-486. Reich K, Papp KA, Blauvelt A, et al. Bimekizumab versus ustekinumab for the treatment of moderate-to-severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Lancet. 2021;397(10273):487-498. Rumberger BE, Boarder EL, Owens SL, et al. Transcriptomic analysis of hidradenitis suppurativa skin suggests roles for multiple inflammatory pathways in disease pathogenesis. Inflamm Res. 2020;69(10):967-973. US-BK-2500704Date of preparation: June 2025BIMZELX® is a registered trademark of the UCB Group of Companies©2025 UCB, Inc., Smyrna, GA 30080, All rights reserved. View original content to download multimedia: SOURCE UCB Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Borneo Post
11-06-2025
- Business
- Borneo Post
Sabah set to shine as global business events hub in 2026
Liew (left) being briefed by Dr Rosmawati (right). KOTA KINABALU (June 11): Sabah will enter the next phase of its journey as a regional business events (BE) hub next year. Sabah International Convention Centre (SICC) chief executive officer Datuk Dr Hajah Rosmawati Lasuki said the third edition of BE in Sabah is scheduled to take place from Feb 4-5 next year under the new theme 'Global Collaboration Through Business Events'. It is jointly organised by SICC and MACEOS Sabah Chapter. 'The 2026 edition will mark a turning point, not just a forum but a full-scale live demonstration of the strength and potential of global business events. 'BE in Sabah 2026 will bring together decision makers, organisers and associations from around the world, not just to connect but to experience the global business events ecosystem in motion,' Dr Rosmawati said when briefing Tourism, Culture and Environment Minister Datuk Seri Panglima Christina Liew on Monday. Sabah, which delivers a seamless, professional experience through a trusted supply chain, world class venues, efficient logistics and rich cultural heritage, is where the world meets and where business events move forward together, she added. Liew said the continued support from her ministry (KePKAS), together with international bodies such as International Congress and Convention Association and local agencies, including the Malaysia Convention & Exhibition Bureau and Malaysian Association of Convention and Exhibition Organisers and Suppliers, has played a pivotal role in elevating BE in Sabah into a respectable regional forum from the time it was first introduced in 2024 to raise greater awareness among local BE players. 'More importantly, aggressive international marketing efforts by Dr Rosmawati and her team have significantly raised the visibility of Sabah on the global business events map. Sabah's participation in the ICCA Congress 2024 in Abu Dhabi, UAE, has borne fruit,' she said. Dr Rosmawati expressed her appreciation for unwavering support from KePKAS and the Chief Minister's Office. 'From high-level dialogues to impactful connections, BE in Sabah is now drawing attention as a serious platform for international business collaboration,' she said. Briefing the minister, she said 161 international delegates representing 29 countries attended this year's edition of BE in Sabah, themed 'Empowering Asia Pacific Through Business Events'. The two-day forum highlighted global insights, sustainability, and strategic partnerships. 'The event also delivered tangible economic returns for Sabah. Direct delegate expenditure was recorded at RM899,364, a significant increase from RM588,800 in 2024. 'Similarly, the total economic impact soared from RM1.38 million in 2024 to RM2.1 million in 2025. This reflects a growing confidence and participation in Sabah's business events landscape. 'Tax revenue also increased from RM35,328 in 2024 to RM53,961 this year, while the number of jobs supported rose from 100 to 120. This indicates broader economic stimulation across the tourism, hospitality, and service sectors,' Dr Rosmawati shared. Also present were the ministry's Permanent Secretary Datuk Josie Lai, SICC Director of Finance Catherina Wee, Assistant Director of Corporate Communications Clara Lim, and Assistant Manager of Corporate Communications Rachel Hee.
News18
05-06-2025
- Sport
- News18
'Don't Cut His Body...': Father Pleads Against His Son's Postmortem After Bengaluru Stampede
Last Updated: A day after stampede broke out during Royal Challengers Bengaluru's IPL win celebration, a father pleaded to not conduct an autopsy on his son, one of the 11 victims. A day after the horrific Bengaluru stampede, which took place when scores of fans gathered to celebrate the first historic Indian Premier League (IPL) win of Royal Challengers Bengaluru, heart-wrenching scenes unfolded as kin of the dead lamented over their loss. In one of the cases, a father appealed to the authorities not to conduct any autopsy on his son, who was killed in the deadly stampede. Bengaluru stampede victim's father breaks down – who will pay for his tears ? — pallavi ghosh (@_pallavighosh) June 5, 2025 'At least give me his body. Don't do a postmortem. Don't cut his body into pieces. I had only one son, and now I have lost him. He came here without informing me. Now the Chief Minister and Deputy Chief Minister may visit, but no one can bring him back," the visibly shattered father pleaded. The son, identified as Bhumik, was among the 11 people who lost their lives in the stampede outside the Chinnaswamy Stadium near the Vidhan Soudha. Bhumik was a BE student and an ardent fan of RCB. 'I never stayed away from him for even an hour. I have raised an only son. I have raised him for 22 years, and now, I see him die on the streets thanks to your attitude. I didn't know that he had come here. Please just hand over my son's body to him. Whatever has happened, has happened," Bhumik's father further said, while speaking to local media. First Published: June 05, 2025, 13:10 IST
Yahoo
29-05-2025
- Business
- Yahoo
ComEd Receives Approval for Beneficial Electrification Plan 2, Continuing to Advance Transportation Electrification in Illinois
Investment of $168 million over three years will support EV purchases and charging infrastructure advancements CHICAGO, May 29, 2025--(BUSINESS WIRE)--ComEd today announced that the Illinois Commerce Commission (ICC) has approved its second Beneficial Electrification (BE) Plan, investing approximately $168 million over a three-year period beginning in 2026. The continuation of ComEd's BE funding marks a significant step forward in ComEd's commitment to advancing electric vehicle (EV) adoption and reducing emissions in northern Illinois. Building on its current $231 million investment in beneficial electrification, deployed from 2023 through 2025, ComEd will invest an additional $168 million between 2026-2028 through BE Plan 2 to help residential and non-residential customers transition to and take advantage of electric vehicles. Since February of 2024, ComEd has incentivized the purchase and installation of nearly 5,000 public and private EV charging ports (Level 2 and Fast Chargers) and the purchase or lease of nearly 1,000 new and pre-owned electric fleet vehicles. More than 70% of the rebates awarded have gone to low-income customers or business and public sector organizations located in, or primarily serving, low-income and Equity Investment Eligible Communities (EIECs). Over this same period, Illinois has seen EV registrations grow three to four times faster than the nation as a whole. "The shift to EVs is a major milestone on the road to Illinois' clean energy future, and it is part of a broader effort to electrify more of our region's energy system," said Gil C. Quiniones, ComEd President and CEO. "Through the expansion of our Beneficial Electrification programs, ComEd is helping to reduce carbon emissions, improve air quality, and enable all communities to enjoy the benefits and opportunities that flow from the global energy transformation." The approval of ComEd's BE Plan 2 follows the successful implementation of ComEd's first BE Plan, which was approved in 2023 under the guidance of the Climate and Equitable Jobs Act (CEJA). Signed into law by Governor J.B. Pritzker in 2021, CEJA aims to combat climate change by leveraging Illinois' clean electricity grid and promoting beneficial electrification across the state. "Illinois is committed to decarbonizing the transportation sector, and ComEd's BE Plan 2 plays a crucial role in enabling more electric vehicle adoption in the state," said Megha Lakhchaura, State EV Officer of Illinois. "By expanding charging infrastructure and providing incentives from the state and key partners like ComEd, we are making EV adoption more accessible and practical for residents and businesses alike." Key components of ComEd's second Beneficial Electrification Plan include: Residential EV Charger and Installation Program: $11 million, over three years, to offer rebates of up to $2,500 per household to support the purchase and installation of residential Level 2 electric vehicle chargers. Business and Public Sector EV Purchase Program: $82 million, over three years, to offer rebates for the purchase or lease of new or pre-owned fleet EVs of all weight classes. Business and Public Sector Make-Ready Program: $44 million, over three years, to offer rebates for covering costs associated with making sites ready for public or private Level 2 of DC Fast Charging equipment. Customer Education and Awareness Program: $11 million, over three years, to fund multiple efforts to empower and support customers to make informed decisions about vehicle electrification and charging infrastructure deployment. This includes free access to ComEd support tools including Fleet Electrification Assessments, EV Toolkits and training programs for municipalities interested in achieving "EV Ready" status, and free Fleet Electrification Assessments, among others. Research and Development Program: $11 million, over three years, to evaluate and demonstrate the impact of new transportation and electrification technologies. Portfolio Program: $9 million, over three years, to fund a variety of initiatives spanning across multiple programs, to support a successful deployment of BE Plan 2 as a whole. Projects located in, or primarily serving, low income or EIECs, will be eligible for higher rebate amounts, and will receive more than 50% of the BE Plan 2 budget. Exact rebate amounts may be adjusted in response to demand over the course of the BE Plan 2 timeline. EVs provide a variety of benefits for customers. Not only do they offer fuel and maintenance cost savings and performance benefits, but communities can experience broad environmental improvements from reduced tailpipe emissions. Additionally, electrifying transportation—especially vehicle fleets—can create tangible benefits for all communities and families across northern Illinois, including health benefits in communities which have traditionally borne the brunt of climate change and air pollution. "Reducing vehicle emissions is one of the most effective ways to improve air quality and public health," said Brian Urbaszewski, Director of Environmental Health Programs at Respiratory Health Association. "Given current uncertainty with other sources of funding that foster zero-emission transportation, ComEd's continued investment in its Beneficial Electrification Plan is now even more critical in helping cut harmful pollutants, leading to cleaner air and healthier communities across northern Illinois." ComEd's BE Plan 2 was developed in close collaboration with multiple stakeholders, including environmental organizations, community groups and industry experts to ensure equitable access to electrification benefits. The continued efforts in 2026 will build upon the existing resources and tools ComEd has already launched to support customer education and EV adoption including, the ComEd EV Toolkit, EV Ambassador Program, EV Readiness program, EV Load Capacity Map, Fleet Electrification Assessments, EV Service Provider Network, EV Dealership Network and more. For more information on ComEd's second BE Plan and available resources and programs offered by ComEd, please visit ComEd is a unit of Chicago-based Exelon Corporation (NASDAQ: EXC), a Fortune 200 energy company serving more than 10.7 million electricity and natural gas customers—the largest number of customers in the U.S. ComEd powers the lives of more than 4 million customers across northern Illinois, or 70 percent of the state's population. For more information, visit and connect with the company on Facebook, Instagram, LinkedIn, X and YouTube. View source version on Contacts ComEdMedia Relations312-394-3500
